A screening system for detecting genetic risk markers of type 1 diabetes in dried blood spots

被引:7
作者
Dantonio, Paul
Meredith, Nancy
Earley, Marie
Cordovado, Suzanne
Callan, William J.
Rollin, Danita
Morris, Deannie
Vogt, Robert F.
Hannon, W. Harry
机构
[1] Ctr Dis Control & Prevent, Div Sci Lab, Newborn Screening Branch, Atlanta, GA 30341 USA
[2] Alabama State Dept Hlth, Bur Clin Labs, Montgomery, AL USA
关键词
D O I
10.1089/dia.2006.8.433
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Certain alleles among the genes that code for the human leukocyte antigens (HLA) confer susceptibility or resistance to the development of autoimmunity that causes type 1 diabetes (T1D). A number of ongoing diabetes research studies analyze dried blood spots (DBS) from newborn infants for HLA-D alleles to identify higher-risk children as early as possible. A commercially available assay to detect such alleles has recently become available using a dissociation-enhanced lanthanide fluorescence system found in many newborn screening laboratories. Methods: We adapted the system for use with DBS and improved the sample set-up for greater efficiency. We also developed an independent system for data analysis based on a spreadsheet program. These modifications were applied to HLA-DQB1 gene locus (DQB) analysis of 117 newborn DBS, and the results we obtained were compared with independent reference values. Results: Our assay modifications and independent data analysis improved sample throughput and result tabulation. DQB results from the modified assay were consistent with the reference values in all but one sample, which showed a partial match. Conclusions: The modifications described here make this commercially available assay more suitable for high-throughput applications such as newborn screening. Our results show that this system allows highly accurate detection of DQB alleles that influence T1D risk.
引用
收藏
页码:433 / 443
页数:11
相关论文
共 26 条
[1]   Predicting type 1 diabetes [J].
Achenbach P. ;
Bonifacio E. ;
Ziegler A.-G. .
Current Diabetes Reports, 2005, 5 (2) :98-103
[2]   Clinical characteristics of children diagnosed with type 1 diabetes through intensive screening and follow-up [J].
Barker, JM ;
Goehrig, SH ;
Barriga, K ;
Hoffman, M ;
Slover, R ;
Eisenbarth, GS ;
Norris, JM ;
Klingensmith, GJ ;
Rewers, M .
DIABETES CARE, 2004, 27 (06) :1399-1404
[3]   A METHOD FOR TYPING POLYMORPHISM AT THE HLA-A LOCUS USING PCR AMPLIFICATION AND IMMOBILIZED OLIGONUCLEOTIDE PROBES [J].
BUGAWAN, TL ;
APPLE, R ;
ERLICH, HA .
TISSUE ANTIGENS, 1994, 44 (03) :137-147
[4]  
Caggana M, 1998, HUM MUTAT, V11, P404, DOI 10.1002/(SICI)1098-1004(1998)11:5<404::AID-HUMU8>3.0.CO
[5]  
2-S
[6]   Treatment of type 1 diabetes with anti-CD3 monoclonal antibody [J].
Glandt, M ;
Hagopian, W ;
Herold, KC .
REVIEWS IN ENDOCRINE & METABOLIC DISORDERS, 2003, 4 (04) :361-368
[7]  
GLASS M, 2002, P 2002 NEWB SCREEN G, P106
[8]   PANDA identifies babies at risk of developing type 1 diabetes [J].
Greener, M .
MOLECULAR MEDICINE TODAY, 2000, 6 (01) :3-3
[9]  
HAGOPIAN W, 2001, P 2001 NEWB SCREEN G, P49
[10]   Genetic screening for individuals at high risk for type 1 diabetes in the general population using HLA Class II alleles as disease markers.: A comparison between three European populations with variable rates of disease incidence [J].
Hermann, R ;
Bartsocas, CS ;
Soltész, G ;
Vazeou, A ;
Paschou, P ;
Bozas, E ;
Malamitsi-Puchner, A ;
Simell, O ;
Knip, M ;
Ilonen, J .
DIABETES-METABOLISM RESEARCH AND REVIEWS, 2004, 20 (04) :322-329